Recombinant T Cell Receptor Ligands: Immunomodulatory, Neuroprotective and Neuroregenerative Effects Suggest Application as Therapy for Multiple Sclerosis

Reviews in the Neurosciences

Volumn 19, Issue 4-5, 2008, Pages 327-340

  Offner, Haiina ^a,a,b,c   Sinha, Sushmita ^a,b   Wang, Chunhe ^a,b   Vandenbark, Arthur A ^a,b,d   Burrows, Gregory G ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b Department of Neurology ^*  (United States)

^c Departments of Anesthesiology   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

experimental autoimmune encephalomyelitis; immunomodulation; multiple sclerosis; neuroprotection; RTL

Indexed keywords

ANTIGEN; BETA INTERFERON; GLATIRAMER; INTERLEUKIN 10; LIGAND; NATALIZUMAB; PLACEBO; RTL 1000; RTL 401; RTL 551; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG STRUCTURE; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INFLAMMATORY CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; MYELINATION; NERVE FIBER DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; MULTIPLE SCLEROSIS; NERVE REGENERATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS;

EID: 57349172905     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2008.19.4-5.327     Document Type: Article

References (51)

1. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-350.
2. Bourdette DN, Vainiene M, Morrison W, Jones R, Turner MJ, Hashim GA, Vandenbark AA, Offner H. Myelin basic protein specific T cell lines and clones derived from the CNS of rats with EAE only recognize encephalitogenic epitopes. J Neurosci Res 1991; 30: 308-315.
3. Burrows GG, Adlard KL, Bebo BF Jr, Chang JW, Tenditnyy K, Vandenbark AA, Offner H. Regulation of encephalitogenic T cells with recombinant TCR ligands. J Immunol 2000; 164: 6366-6371.
4. Burrows GG, Bebo BF Jr, Adlard KL, Vandenbark AA, Offner H. Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. J Immunol 1998; 161: 5987-5996.
5. Burrows GG, Chang JW, Bachinger HP, Bourdette DN, Offner H, Vandenbark AA. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng 1999; 12: 771-778.
6. Burrows GG, Chou YK, Wang C, Chang JW, Finn TP, Culbertson NE, Kim J, Bourdette DN, Lewinsohn DA, Lewinsohn DM, Ikeda M, Yoshioka T, Allen CN, Offner H, Vandenbark AA. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J Immunol 2001; 167: 4386-4395.
7. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1ß. Ann Neurol 1997; 41: 669-674.
8. Cammarota G, Scheirle A, Takacs B, Doran DM, Knorr R, Bannworth W, Guardiola J, Sinigaglia F. Identification of a CD4 binding site on the B2 domain of HLADR molecules. Nature 1992; 356: 799-802.
9. Chang JW, Mechling DE, Bachinger HP, Burrows GG. Design, engineering, and production of human recombinant T cell receptor ligands derived from human leukocyte antigen DR2. J Biol Chem 2001; 276: 24170-24176.
10. Cua DJ, Groux H, Hinton DR, Stohlman SA, Coffinan RL. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med 1999; 189: 1005-1010.
11. D'Souza S, Alinauskas K, McCrea E, Goodyer C, Antel JP. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci 1995; 15: 7293-7300.
12. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, Chien Y. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol 1998; 16: 523-544.
13. Doherty PC, Zinkernagel RM. T-cell-mediated immunopathology in viral infections. Transplant Rev 1974; 19: 89-120.
14. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007; 68 (Suppl 3): S22-31; discussion S43-54.
15. Garcia KC, Degano M, Pease LR, Huang M, Peterson PA, Teyton L, Wilson IA. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998; 279: 1166-1172.
16. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989; 246 668-670.
17. Huan J, Subramanian S, Jones R, Rich C, Link J, Mooney J, Bourdette DN, Vandenbark AA, Burrows GG, Offner H. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J Immunol 2004; 172: 4556-4566.
18. Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 1994; 368: 744-746.
19. Kersh GJ, Allen PM. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med 1996; 184: 1259-1268.
20. Konig R, Huang L.-Y., Germain RN. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 1992; 356: 796-799.
21. Korn T, Reddy J, Gao W, Betteiii E, Awasthi A, Petersen TR, Backstrom BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK. Myelinspecific regulatory ? cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007; 13: 423-431.
22. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1 a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-1513.
23. Link JM, Rich CM, Korat M, Burrows GG, Offher H, Vandenbark AA. Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clin Immunol 2007; 123: 95-104.
24. Matejuk A, Dwyer J, Hopke C, Vandenbark AA, Offner H. Opposing roles for TGF-betal and TGF-beta3 isoforms in experimental autoimmune encephalomyelitis. Cytokine 2004; 25:45-51.
25. Offiier H, Subramanian S, Wang C, Afentoulis M, Vandenbark AA, Huan J, Burrows GG. Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury. J Immunol 2005; 175: 4103-4111.
26. Oksenberg JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS, Shimonkevitz R, Sherritt M, Rothbard J, Bernard CC, et al. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 1993; 362: 68-70.
27. Pastor MI, Woodrow M, Cantrell D. Regulation and function of p21ras in T lymphocytes. Cancer Surv 1995; 22: 75-83.
28. Paterson PY. Multiple sclerosis: an immunologic reassessment. J Chronic Dis 1973; 26: 119-126.
29. Quill H, Schwartz RH. Stimulation of normal inducer T cell clones with antigen presented by purified la molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987; 138: 3704-3712.
30. Rabinowitz JD, Beeson C, Wulfing C, Tate K, Allen PM, Davis MM, McConnell HM. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 1996; 5: 125-135.
31. Rammohan KW. Axonal injury in multiple sclerosis. Curr Neurol Neurosci Rep 2003; 3: 231-237.
32. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356: 2622-2629.
33. Redpath S, Alam SM, Lin CM, O'Rourke AM, Gascoigne NR. Cutting edge: trimolecular interaction of TCR with MHC class II and bacterial superantigen shows a similar affinity to MHC: peptide ligands. J Immunol 1999; 163: 6-10.
34. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64: 1336-1342.
35. Rich C, Link JM, Zamora A, Jacobsen H, Meza Romero R, Offner H, Jones R, Burrows GG, Fugger L, Vandenbark AA. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol 2004; 34: 1251-1261.
36. Rieckmann P, Smith KJ. Multiple sclerosis: more than inflammation and demyelination. Trends Neurosci 2001; 24: 435-437.
37. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996; 184: 1-8.
38. Sinha S, Subramanian S, Proctor TM, Kaier LJ, Grafe M, Dahan R, Huan J, Vandenbark AA, Burrows GG, Offner H. A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS. J Neurosci 2007; 27: 12531-12539.
39. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-619.
40. Szelenyi J. Cytokines and the central nervous system. Brain Res Bull 2001; 54: 329-338.
41. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341: 541-544.
42. Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, Huan J, Fugger L, Offner H, Jones R, Burrows GG. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLADR2 transgenic mice. J Immunol 2003; 171: 127-133.
43. Vandenbark AA, Vainiene M, Celnik B, Hashim GA, Buenafe A, Offner H. Definition of encephalitogenic and immunodominant epitopes of guinea pig myelin basic protein (Gp-BP) in Lewis rats tolerized neonatally with Gp-BP or Gp-BP peptides. J Immunol 1994; 153: 852-861.
44. Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72.
45. Wang C, Gold BG, Kaler LJ, Yu X, Afentoulis ME, Burrows GG, Vandenbark AA, Bourdette DN, Offner H. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 2006; 98: 1817-1827.
46. Wang C, Mooney JL, Meza-Romero R, Chou YK, Huan J, Vandenbark AA, Offner H, Burrows GG. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol 2003; 171: 1934-1940.
47. Waxman SG. Demyelinating diseases-new pathological insights, new therapeutic targets. N Engl J Med 1998; 338: 323-325.
48. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
49. Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-1324.
50. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76: 263-274.
51. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.